International Journal of Clinical Oncology最新文献

{"title":"Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program.","authors":"Junko Tanizaki, Kan Yonemori, Yuichi Takiguchi, Kohei Akiyoshi, Keigo Komine, Yusuke Onozawa, Mariko Sato, Kenro Hirata, Takuma Onoe, Ryotaro Ohkuma, Yosuke Horita, Hironobu Minami, Kazunori Honda, Koichi Suyama, Akihiko Ito, Yasutaka Chiba, Hiroko Watanabe, Yosuke Togashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa, Hidetoshi Hayashi","doi":"10.1007/s10147-026-03187-9","DOIUrl":"https://doi.org/10.1007/s10147-026-03187-9","url":null,"abstract":"<p><strong>Background: </strong>Cancer of unknown primary (CUP) remains a challenging malignancy with a poor prognosis. Although immune checkpoint inhibitors have shown activity in CUP, available data remains limited. We describe clinical outcomes and a comprehensive biomarker analysis from an expanded access trial of nivolumab in CUP.</p><p><strong>Methods: </strong>Patients with CUP were enrolled regardless of treatment history and received intravenous nivolumab (240 mg every 2 weeks or 480 mg every 4 weeks) until disease progression, unacceptable toxicity, or withdrawal. Enrollment concluded after regulatory approval of nivolumab for CUP in Japan. The primary objective was safety; secondary endpoints addressed efficacy, and exploratory biomarker analyses were performed.</p><p><strong>Results: </strong>A total of 53 patients (31 previously treated, 22 untreated) received nivolumab. Adverse events (AEs) occurred in 77.4% of patients, including 24.5% grade 3-4 and 15.1% serious AEs; no treatment-related deaths occurred. The objective response rate was 17.0% (95% confidence interval [CI] 8.1-29.8%) overall and 20.5% (95% CI 9.8-35.3%) in the response-evaluable subset. Median progression-free survival was 4.5 months (95% CI 2.9-7.9) and median overall survival was 17.5 months (95% CI 11.9-25.1). Higher PD-L1 expression was associated with better efficacy, whereas no meaningful differences were observed across estimated tissue-of-origin subgroups.</p><p><strong>Conclusions: </strong>This study provides additional prospective evidence consistent with the preceding NivoCUP trial, supporting the reproducibility of the efficacy and safety of nivolumab for patients with CUP. These findings support PD-1-targeted therapy as a feasible treatment option for this rare malignancy.</p><p><strong>Trial registration: </strong>Japan Registry of Clinical Trials (jRCT) identifier, jRCT2051200146.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of diabetes or hypertension in smokers with CRPC receiving enzalutamide or abiraterone.","authors":"Takashi Fukagai, Kouji Izumi, Motoki Yamagishi, Takashi Shima, Yuki Kato, Koji Mita, Takehiko Okamura, Shogo Inoue, Shuichi Tatarano, Nobumichi Tanaka, Noriyasu Kawai, Manabu Kamiyama, Ippei Chikazawa, Seiji Hoshi, Kohei Hashimoto, Kazuyoshi Shigehara, Shizuko Takahara, Atsushi Mizokami","doi":"10.1007/s10147-026-03178-w","DOIUrl":"https://doi.org/10.1007/s10147-026-03178-w","url":null,"abstract":"<p><strong>Background: </strong>Smoking and lifestyle‑related diseases increase the risk of cancer incidence and progression, but their impact on castration‑resistant prostate cancer (CRPC) remains unclear. This study examined whether diabetes mellitus (DM), hypertension (HT), and smoking habit (SH) affect the prognosis of CRPC patients treated with enzalutamide (ENZ) or abiraterone plus prednisolone (ABI).</p><p><strong>Methods: </strong>Using data from the ENABLE study for PCa, an investigator‑initiated, multicenter, randomized controlled trial, patients were retrospectively categorized into two groups based on SH. Subsequently, the impact of the absence or presence of either DM or HT and treatment arm (ENZ or ABI) on survival endpoints was investigated.</p><p><strong>Results: </strong>A total of 178 patients were randomized and treated, of whom 161 had available SH information and were included in the analysis (84 SH- and 77 SH+). No significant differences in survival endpoints were observed between the SH- and SH+ groups. In the SH+ group, prostate cancer-specific survival (PCSS) was significantly worse in the with‑DM/HT group than in the no‑DM/HT group (p = 0.0215). Multivariate Cox analysis confirmed that the presence of DM or HT was an independent predictor of poor PCSS. Furthermore, a significant difference in PCSS between the no‑DM/HT and with‑DM/HT groups was observed in the ENZ arm (p = 0.0201), but not in the ABI arm.</p><p><strong>Conclusions: </strong>SH does not appear to influence the efficacy of ENZ or ABI therapy for CRPC; however, among SH+ patients, the presence of DM or HT was associated with poorer survival outcomes, particularly in those treated with ENZ.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse event risks and prognostic factors associated with endoscopic laryngopharyngeal surgery for superficial head and neck cancer after chemoradiotherapy.","authors":"Sakiko Naito, Hayato Yamaguchi, Masakatsu Fukuzawa, Isaku Okamoto, Kiyoaki Tsukahara, Takao Itoi","doi":"10.1007/s10147-026-03186-w","DOIUrl":"https://doi.org/10.1007/s10147-026-03186-w","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic laryngopharyngeal surgery (ELPS) is an organ-preserving treatment for superficial head and neck squamous cell carcinoma (sHNSCC). While ELPS shows favorable outcomes in primary and metachronous lesions, its role as salvage treatment following chemoradiotherapy (CRT) remains unclear. We evaluated the clinical outcomes of salvage ELPS and factors associated with adverse events (AEs) and prognosis.</p><p><strong>Methods: </strong>Among 136 patients undergoing ELPS between 2014 and 2024, we retrospectively analyzed 17 diagnosed with sHNSCC following CRT. Patients were categorized into salvage and metachronous groups, and clinical characteristics, treatment outcomes, AEs, and survival were compared.</p><p><strong>Results: </strong>The en bloc resection rate was 100%. AEs occurred in 47.1% of patients and were more frequent in the salvage group than in the metachronous group (70.0% vs. 14.3%, p=0.024). Body mass index (BMI) <18.5 kg/m² was significantly associated with AEs (p=0.043). 4-year overall survival (OS) did not differ significantly between groups (83.3% vs. 71.4%), while 12-month relapse-free survival tended to be lower in the salvage group (68.6% vs. 85.7%). BMI was also associated with OS: patients with BMI ≥18.5 kg/m² had a 4-year OS of 81.8%, compared with 50% for patients with BMI <18.5 kg/m² (p=0.036).</p><p><strong>Conclusion: </strong>Salvage ELPS for sHNSCC was associated with a higher AE risk but showed long-term survival outcomes comparable to metachronous ELPS. Nutritional status, particularly low BMI, is a key determinant of safety and prognosis. These findings support the feasibility of ELPS as an organ-preserving strategy and emphasize the importance of careful patient selection and nutritional assessment in salvage settings.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer.","authors":"Masahiro Hatori, Rei Arafune, Kenichi Suzuki, Takashi Yokokawa, Kazuyoshi Kawakami, Eiji Nakatani, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Naoki Sasahira, Masato Ozaka, Hiroshi Ishii, Masakazu Yamaguchi, Kunihiko Itoh, Daiki Tsuji","doi":"10.1007/s10147-026-03201-0","DOIUrl":"https://doi.org/10.1007/s10147-026-03201-0","url":null,"abstract":"<p><strong>Background: </strong>Gemcitabine plus nanoparticle albumin-bound-paclitaxel (GnP) therapy cause sometimes severe neutropenia in all the treatment period, which was reported to association with overall survival (OS). However, the relationship between pharmacokinetics-related genetic polymorphisms and both OS and early severe neutropenia in patients with metastatic pancreatic cancer receiving GnP therapy has not been adequately examined. We aimed to examine the associations between pharmacokinetic genetic polymorphisms involved in GnP, early severe neutropenia, and OS in Japanese patients with metastatic pancreatic cancer treated with GnP as first-line chemotherapy.</p><p><strong>Methods: </strong>This multicenter prospective observational study enrolled 122 patients with metastatic pancreatic cancer who received GnP therapy. Twenty-two genetic polymorphisms related pharmacokinetics of GnP including ABCB1 were analyzed. Multivariable logistic regression and time-dependent Cox proportional hazards models were used to evaluate associations between these genotypes and early severe neutropenia up to day 14 and OS after applied inverse probability of treatment weighting. The significance level was set at 5%.</p><p><strong>Results: </strong>Patients who developed early severe neutropenia had significantly longer median OS (523 vs. 249 days; adjusted hazard ratio [HR], 0.47; 95% confidence interval, 0.26-0.85; p = 0.012). The combination of ABCB1 rs2032582 non-GG and rs1045642 non-CC were significantly associated with severe neutropenia (adjusted odds ratio, 2.75; p = 0.020) and OS (adjusted HR, 0.56; p = 0.017).</p><p><strong>Conclusions: </strong>Early-onset severe neutropenia could be associated with prolonged OS in patients with metastatic pancreatic cancer treated with GnP. The combination of ABCB1 rs2032582 non-GG and rs1045642 non-CC may help predict the risk of severe neutropenia and OS.</p><p><strong>Trial registration: </strong>UMIN 000012720.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world perioperative systemic treatment patterns and postoperative mortality in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy in Japan: WAKKA-UTUC study.","authors":"Junichi Inokuchi, Jumpei Tokumaru, Daisuke Kawai, Ryotaro Ide, Hiroshi Komazaki, Hiroshi Kitagawa, Eiji Kikuchi","doi":"10.1007/s10147-026-03198-6","DOIUrl":"https://doi.org/10.1007/s10147-026-03198-6","url":null,"abstract":"<p><strong>Background: </strong>To characterize the longitudinal changes in perioperative systemic treatment patterns and postoperative mortality among Japanese patients with stage II-IV upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU).</p><p><strong>Methods: </strong>This retrospective observational study used a nationwide Japanese database to evaluate neoadjuvant chemotherapy (NAC) and adjuvant therapy (AT) before and after RNU. Treatment patterns, specific regimens, and 30- and 90-day postoperative mortality were analyzed descriptively across three periods: 2013-2017, 2018-2021, and 2022-2024.</p><p><strong>Results: </strong>Among 6,165 patients included in the study, the use of AT without prior NAC increased from 25.7% in 2013-2017 to 30.0% in 2022-2024, and the proportion of patients who received any NAC increased from 9.8% to 17.1%, respectively. By 2022-2024, gemcitabine plus carboplatin emerged as the most widely used regimen for NAC and AT (6.5% and 15.2% of the overall study population during this period [n = 1,482], respectively). Adjuvant nivolumab was administered to 142 patients (9.6% of all patients undergoing RNU in 2022-2024), but most (n = 84) had not received prior NAC. Postoperative mortality remained stable across the study periods (30-day mortality: 0.0%-0.5%; 90-day mortality: 0.3%-2.0%), with no increase in mortality among patients who received NAC.</p><p><strong>Conclusions: </strong>The use of perioperative systemic therapy for UTUC in Japan increased over the study period, with growing adoption of NAC, AT, and adjuvant nivolumab. Postoperative mortality remained stable, showing no notable association with NAC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.","authors":"Takayasu Kurata, Shunichi Sugawara, Hiroaki Akamatsu, Kazushige Wakuda, Koichi Azuma, Takayuki Takahama, Hiroshi Kagamu, Hiroshi Yokouchi, Miyako Satouchi, Shuji Murakami, Kadoaki Ohashi, Makoto Nishio, Kazumi Nishino, Hiroki Izumi, Hiroshi Tanaka, Taichi Miyawaki, Shuang Huang, Upen Patil, Jihyun Park, Tatsuya Yoshida","doi":"10.1007/s10147-026-03192-y","DOIUrl":"https://doi.org/10.1007/s10147-026-03192-y","url":null,"abstract":"<p><strong>Background: </strong>In the Phase 3 DeLLphi-304 trial, tarlatamab significantly improved overall survival (OS) over chemotherapy for small-cell lung cancer (SCLC) progressed after platinum-based chemotherapy. We report efficacy and safety in the Japanese subpopulation.</p><p><strong>Methods: </strong>Patients were randomized to tarlatamab or amrubicin in Japan. The primary endpoint was OS. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and safety.</p><p><strong>Results: </strong>As of 29 Jan 2025 (data cutoff), 35 patients (tarlatamab, n = 12; amrubicin, n = 23) were enrolled. Baseline characteristics were generally balanced although fewer tarlatamab-treated patients had chemotherapy-free interval < 90 days or brain metastases. Median OS was NE (95% CI, 10.4, NE) for tarlatamab versus 11.5 (6.2, NE) months for amrubicin (HR [95% CI] = 0.533 [0.186, 1.529]). Twelve-month survival was 66.7% (33.7, 86.0) versus 47.0% (25.7, 65.6), respectively. Median PFS was 4.0 (1.3, 11.3) months versus 4.2 (2.1, 5.4) months (HR [95% CI] = 0.726 [0.339, 1.554]). ORR was 33.3% (9.9, 65.1) versus 26.1% (10.2, 48.4). Median DOR was 10.1 (3.0, NE) months versus 5.6 (2.8, NE) months. Grade ≥ 3 treatment-related adverse events were less frequent with tarlatamab (8.3%) versus amrubicin (56.5%). Cytokine release syndrome occurred in 75% of tarlatamab-treated patients (all were grade 1 or 2) and grade 2 immune effector cell-associated neurotoxicity syndrome was reported in 1 (8.3%) patient.</p><p><strong>Conclusion: </strong>Tarlatamab demonstrated numerically longer OS and DOR, and higher ORR versus amrubicin in Japanese patients with SCLC, with fewer high-grade treatment-related adverse events. These results in Japanese patients support those of the global population.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical activity of platinum rechallenge with nedaplatin plus irinotecan in recurrent cervical cancer following prior platinum-based systemic chemotherapy: a single-center retrospective study.","authors":"Yoshifumi Takahashi, Yuji Takei, Miku Takadera, Masahiro Taguchi, Nozomi Ogawara, Eri Suizu, Kazuki Yamamoto, Kohei Tamura, Miki Shinohara, Takahiro Koyanagi, Akiyo Taneichi, Yasushi Saga, Hiroyuki Fujiwara","doi":"10.1007/s10147-026-03196-8","DOIUrl":"https://doi.org/10.1007/s10147-026-03196-8","url":null,"abstract":"<p><strong>Background: </strong>Treatment options remain limited for patients with recurrent cervical cancer following prior platinum-based systemic chemotherapy. Despite the activity of nedaplatin plus irinotecan in recurrent cervical cancer, its clinical value as a platinum rechallenge regimen following prior platinum-based systemic chemotherapy remains unclear. This study examined the efficacy and safety of this combination therapy in this setting.</p><p><strong>Methods: </strong>Patients with recurrent cervical cancer who received at least 1 cycle of nedaplatin plus irinotecan after recurrence or progression following prior platinum-based systemic chemotherapy at Jichi Medical University Hospital between January 2018 and December 2025 were retrospectively analyzed. Treatment efficacy and safety were evaluated, and survival outcomes were estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>This study included 26 patients. The median platinum-free interval was 3 months, and 21 patients received nedaplatin plus irinotecan as a second-line platinum-containing systemic chemotherapy. The objective response rate among patients with measurable disease was 23.8%, whereas the disease control rate among all evaluable patients was 53.8%. The median progression-free survival was 5.0 months, whereas the median overall survival was 22.5 months. Grade ≥ 3 hematologic adverse events included neutropenia in 15 patients, anemia in 9, and thrombocytopenia in 5. No treatment-related death occurred.</p><p><strong>Conclusions: </strong>Nedaplatin plus irinotecan demonstrated clinically meaningful activity with manageable toxicity in selected patients with recurrent cervical cancer following prior platinum-based systemic chemotherapy. Platinum rechallenge may be a potential treatment option in this setting, although further studies are warranted to identify patients most likely to benefit.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148989711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct risk profiles of heart failure and non-heart failure major adverse cardiovascular events among patients with early breast cancer: a competing-risk analysis.","authors":"Hideo Shigematsu, Atsuyoshi Norishige, Kazuaki Tanabe, Hiroyuki Sawatari, Yukiko Nakano, Ai Amioka, Daiki Okamoto, Sakiko Hino, Haruka Ikejiri, Shinsuke Sasada, Morihito Okada","doi":"10.1007/s10147-026-03200-1","DOIUrl":"https://doi.org/10.1007/s10147-026-03200-1","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular complications are increasingly recognized among patients with breast cancer; however, heart failure has been the primary focus of studies to date. We aimed to evaluate the cumulative incidence of heart failure and other major adverse cardiovascular events among patients with early breast cancer and to identify risk factors.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of patients with non-metastatic breast cancer who underwent curative surgery at a tertiary center during 2010-2019. The endpoints were heart failure and other major adverse cardiovascular events (stroke, atrial fibrillation, myocardial infarction, or cardiovascular death). The cumulative incidence was estimated using the cumulative incidence function, and risk factors were evaluated using Fine-Gray competing-risk regression models. Breast cancer recurrence and non-cardiovascular event-related death were treated as competing events.</p><p><strong>Results: </strong>Over a median follow-up of 7.7 years, heart failure occurred in 24/1,328 (1.8%) patients, whereas other major adverse cardiovascular events occurred in 38 (2.9%). The cumulative incidence of heart failure differed according to perioperative systemic therapy (p = 0.002). Anthracycline use (subdistribution hazard ratio, 2.67; 95% confidence interval, 1.08-6.65; p = 0.034) and trastuzumab use (2.52; 1.00-6.33; p = 0.050) were independently associated with heart failure. By contrast, other major adverse cardiovascular events were associated with age (> 65 years; 3.75; 1.59-8.88; p = 0.003) and cardiovascular risk factors (4.02; 1.77-9.10; p < 0.001).</p><p><strong>Conclusions: </strong>Heart failure was primarily associated with cardiotoxic cancer therapies, and other events by patient-related cardiovascular risk factors. These findings highlight the importance of integrating cardiotoxicity surveillance with long-term cardiovascular risk management in breast cancer survivorship.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Efficacy and safety of endoscopic resection followed by chemoradiotherapy with S-1 plus cisplatin for esophageal cancer.","authors":"Yasuhiro Tani, Ryu Ishihara, Sachiko Yamamoto, Minoru Kato, Shunsuke Yoshii, Satoki Shichijo, Takashi Kanesaka, Koji Higashino, Noriya Uedo, Tomoki Michida, Koji Konishi","doi":"10.1007/s10147-026-03195-9","DOIUrl":"https://doi.org/10.1007/s10147-026-03195-9","url":null,"abstract":"","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.","authors":"Tetsuro Ochi, Shinichi Makita, Anna Hiratsuka, Risa Nishiyama, Kimiteru Ito, Akiko Miyagi Maeshima, Wataru Takeda, Noriko Iwaki, Suguru Fukuhara, Wataru Munakata, Koji Izutsu","doi":"10.1007/s10147-026-03189-7","DOIUrl":"https://doi.org/10.1007/s10147-026-03189-7","url":null,"abstract":"","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148929923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}